Phase II study of paclitaxel in pretreated advanced gastric cancer

Anti-Cancer Drugs

Volumn 9, Issue 4, 1998, Pages 307-310

  Cascinu, Stefano ^a   Graziano, Francesco ^a   Cardarelli, Nadia ^b   Marcellini, Massimo ^b   Giordani, Paolo ^a   Menichetti, Ettore Tito ^b   Catalano, Giuseppina ^a  

^a SAN SALVATORE HOSPITAL   (Italy)

^b Servizio di Oncologia Medica   (Italy)

Author keywords

Advanced gastric cancers; Chemotherapy; Paclitaxel

Indexed keywords

CISPLATIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; DRUG SCREENING; FEMALE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMACH CANCER; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0031746523     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199804000-00003     Document Type: Article

References (15)

1. Macdonald JS. Gastric cancer: chemotherapy of advanced disease. Hematol/Oncol 1992; 10: 37-42.
2. Schipper DL, Wagener DJT. Chemotherapy of gastric cancer. Anti-Cancer Drugs 1996; 7: 137-49.
3. Rowinsky EK, Cazenave LA, Donehower RC. Taxol: a novel investigational antimicrotubule agent. J Natt Cancer Inst 1990; 82: 1247-59.
4. McGuire WP, Rowinsky EK, eds. Paclitaxel in cancer treatment. New York: Marcel Dekker 1995.
5. Chang YF, Li LL, Wu CW, Liu TY, Peng FK, Chi CW. Paclitaxel-induced apoptosis in human gastric carcinoma cell lines. Cancer 1996; 77: 14-8.
6. Einzig AI, Wiernik PH, Lipsitz S, Benson AB. Phase II trial of taxol in patients with adenocarcinoma of the upper gastrointestinal tract: the Eastern Cooperative Oncology Group results. Proc Am Soc Clin Oncol 1993; 12: 566.
7. Ajani JA, Ilson DH, Kelsen DP. Paclitaxel in the treatment of patients with upper gastrointestinal carcinomas. Semin Oncol 1996; 23: 55-8.
8. Cascinu S, Ficarelli R, Aziz MM, Graziano F, Catalano G, Cellerino R. A phase I study of paclitaxel and 5-fluorouracil in advanced gastric cancer. Eur J Cancer 1997; 33: 1699-702.
9. NCI. Guidelines for reporting of adverse drug reactions: cancer therapy evaluation programme. Washington, DC: NCI 1990: 1-17.
10. Miller AB, Hoodgstraten B, Staquet M, Winlker A. Reporting results of cancer treatment. Cancer 1981; 47: 207-11.
11. Buyse ME, Staquet MJ, Silvester RJ. Cancer clinical trials: methods and practice. Oxford: Oxford Medical 1990; 214-21.
12. Kambe M, Wakui A, Nakao I, et al. A late phase II study of irinotecan (CPT-11) in patients with advanced gastric cancer. Proc Am Soc Clin Oncol 1993; 12: 584.
13. Sulkcs A, Smyth J, Sessa C, et al. Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. Br J Cancer 1994; 70: 380-3.
14. Wahl AF, Donaldson KL, Fairchild C. Loss of normal p53 function confers sensitization to taxol by increasing G2/M arrest and apoptosis. Nat Med 1996; 2: 72-9.
15. Tahara E, Semba S, Tahara H. Molecular observations in gastric cancer Semin Oncol 1996; 23: 307-15.